Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract

NCT01031420 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT01031420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01031420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2009
Completion date
August 7, 2013
Enrollment
54 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high risk urothelial carcinoma of the upper urinary tracts, muscle invasive bladder cancer